KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Capital Leases (2016 - 2025)

Regeneron Pharmaceuticals has reported Capital Leases over the past 16 years, most recently at $720.0 million for Q4 2025.

  • Quarterly results put Capital Leases at $720.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $720.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $720.0 million, changed 0.0%.
  • Capital Leases for Q4 2025 was $720.0 million at Regeneron Pharmaceuticals, roughly flat from $720.0 million in the prior quarter.
  • Over the last five years, Capital Leases for REGN hit a ceiling of $720.0 million in Q1 2022 and a floor of $720.0 million in Q1 2022.
  • Median Capital Leases over the past 4 years was $720.0 million (2022), compared with a mean of $720.0 million.
  • Peak annual rise in Capital Leases hit 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
  • Regeneron Pharmaceuticals' Capital Leases stood at $720.0 million in 2022, then changed by 0.0% to $720.0 million in 2023, then changed by 0.0% to $720.0 million in 2024, then changed by 0.0% to $720.0 million in 2025.
  • The last three reported values for Capital Leases were $720.0 million (Q4 2025), $720.0 million (Q3 2025), and $720.0 million (Q2 2025) per Business Quant data.